B-CELL MATURATION ANTIGEN-CD3-DIRECTED BISPECIFIC ANTIBODY IMMUNOTHERAPY
Elrexfio is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with relapsed or refractory multiple myeloma who’ve received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Elrexfio is also referred to by its drug name, elranatamab-bcmm.
Elrexfio is a B-cell maturation antigen (BCMA)-CD3-directed bispecific antibody immunotherapy. Elrexfio is believed to work by binding to BCMA on myeloma cells and to CD3 on T cells. This action brings these cells together and stimulates the T cells to eliminate the myeloma cells effectively.
How do I take it?
Prescribing information states that Elrexfio is taken by injection on a step-up dosing schedule through day eight, a weekly dosing schedule through week 24, and a biweekly dosing schedule from week 25 and on.
Elrexfio is given as a subcutaneous (under the skin) injection.
The FDA-approved label for Elrexfio lists common side effects including cytokine release syndrome (CRS), fatigue, injection site reactions (redness, itching, pain, bruising, rash, swelling, and tenderness), diarrhea, upper respiratory tract infection, bone and muscle pain, pneumonia, decreased appetite, rash, cough, nausea, and fever. The most common severe abnormal lab test results include decreased white blood cells, red blood cells, and platelets.
Rare but serious side effects listed for Elrexfio include infections, low levels of neutrophils, liver damage, and fetal harm or embryo-fetal toxicity.
The FDA-approved label for Elrexfio includes a warning that CRS and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome, can occur in people receiving Elrexfio.
For more details about this treatment, visit:
Elrexfio (Elranatamab-Bcmm) — Pfizer
Elrexfio (Elranatamab-Bcmm) — International Myeloma Foundation